PDCD1 and head and neck squamous cell carcinoma: Towards this goal, immune gene expression profile (GEP) scores via analysis of extracted RNA, characterize the “T cell activation status” in the tumor microenvironment, and have been observed to predict anti-PD-1 efficacy across various tumor types, including HNSCC [14, 61–64].